Apellis' eye med application on track for next year after FDA OKs inclusion of phase 2 data

After posting mixed phase 3 readouts in September, Apellis Pharmaceuticals' investigational eye drug pegcetacoplan is poised to hit the FDA's desk in geographic atrophy with a mix of mid- and late-stage data.

The FDA gave Apellis the OK to use safety and efficacy data from two phase 3 trials, Derby and Oaks, plus the phase 2 Filly trial, when it files the drug for approval in geographic atrophy secondary to age-related macular degeneration in the first half of 2022. The company said it doesn't believe it will need to run any additional studies.